Zydus Lifesciences' Saroglitazar shows higher MASH resolution rates than placebo in phase 2b trial

Zydus Therapeutics reported that its investigational drug saroglitazar achieved resolution of steatohepatitis without worsening of fibrosis in 39.1% of patients receiving the 4 mg…

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.cnbctv18.com)